Bloomberg Intelligence Podcast — Episode Summary

Episode: Metsera Tumbles After Novo Pulls Out of Bidding War With Pfizer
Date: November 10, 2025
Hosts: Paul Sweeney, Scarlet Fu (Bloomberg Intelligence)
Featured Analysts: Sam Frazelli, Mandeep Singh, Jennifer Bartashus

Episode Overview

The episode dives deep into significant company developments and market dynamics, centered on:

• The collapse of Novo Nordisk’s bid for Metsera, a US maker of an experimental weight-loss drug, yielding victory to Pfizer.
• Broader implications for the competitive landscape in obesity drugs, the pharmaceutical sector, and how incumbents like Eli Lilly are positioned.
• Analysis of semiconductor giant TSMC in light of recent growth figures and its role as the backbone of the AI chip supply chain.
• A check-in on Tyson Foods’ earnings and the structural drivers of high beef prices in America, topped by thoughts on poultry pricing for the holiday season.

1. Metsera Bidding War: Novo Nordisk vs. Pfizer

[01:55 - 07:36]

Key Points & Insights

• Metsera’s Weight Loss Drug Attracts Bidders

  • Both Novo Nordisk and Pfizer vied for Metsera, which specializes in an experimental weight-loss (GLP-1) drug.
  • Fierce interest reflects the sector’s search for new obesity solutions.

• Clinical Strengths and Questions

  • Sam Frazelli noted that Metsera had recently clarified data on its once-monthly GLP-1 candidate, with side effects on par with similar drugs: common nausea and vomiting early in treatment, resolving over time ([02:37]).
  • “If you can withstand them, you seem to get the benefit and it seems to work pretty well as a once monthly drug. But there's always more wood to be chopped.” — Sam Frazelli [02:50]

• Regulatory Risks Led Novo Nordisk to Withdraw

  • Novo Nordisk’s deal faced antitrust risks; the FTC warned Metsera that approval might be blocked, tipping advantage to Pfizer ([03:40]).
  • “It sounds like the FTC had given Metsehra a call saying, look, if you go with [Novo] there is a risk it won't close, so do whatever you think is the right thing for your shareholders.” — Sam Frazelli [03:48]

• Market Implications for Novo Nordisk & Eli Lilly

  • Despite “losing” the bidding war, Novo isn’t out—though its pursuit indicates a need to bolster its obesity asset pipeline ([04:15]).
  • “I wouldn't call them desperate, but they obviously by going after this they did say that we need more assets in our bank.” — Sam Frazelli [04:18]
  • The market is currently favoring Eli Lilly, whose drugs are showing stronger performance; Lilly was notably absent from the bidding war ([04:40]).

• Industry Dynamics: ‘Haves and Have-Nots’

  • Pharma stocks are increasingly bifurcated: strong obesity exposure means share price gains; others lag ([05:12]).
  • Neuroscience and cardiovascular fields are seeing more pharma investment, showing the sector is broadening beyond just obesity ([05:38]).

• Eli Lilly’s Position

  • “I think Eli Lilly is currently very well placed with the assets that they have today to compete. And they're showing that they're competing very, very effectively and in some cases winning market share from Novo Nordisk.” — Sam Frazelli [06:42]

• Closing Thought: US Medical Funding

  • Sam expressed concern over President Trump’s threats to cut medical and STEM research funding, seeing such moves as damaging to US economic and scientific leadership ([07:11]).

2. Semiconductor Deep Dive: TSMC & the AI Gold Rush

[10:37 - 18:14]

Key Points & Insights

• TSMC: AI Growth, Capacity Constraints & Diversification

  • Taiwan Semiconductor Manufacturing Co. (TSMC) reported slower monthly sales growth (16.9%, slowest in 18 months) but remains on track ([12:51]).
  • AI now makes up ~15% of TSMC’s revenues; demand is strong, especially for cutting-edge “leading nodes,” where TSMC is unrivaled ([13:13]).
  • “Everyone is putting their dollars in AI capex, but then they have to take away spending from elsewhere. And so the non AI piece of the hardware spend that seems to be slowing down…” — Mandeep Singh [11:54]

• TSMC’s Competitive Moat

  • US tech giants are working on their own chips, but no imminent challenger to TSMC’s foundry dominance exists. Intel’s manufacturing investments are not yet seen as a threat ([14:27]).
  • “For now there is nothing on the horizon where you think an OpenAI or any of these chip companies is going to go to Intel for manufacturing their chips.” — Mandeep Singh [14:59]
  • UMC, once a peer, is “kind of a shadow of its former self”; TSMC’s efficiency and technological leadership are virtually unchallenged ([16:17]).
  • “TSMC, it feels like they have an unassailable moat and not just in terms of manufacturing but also their efficiency when it comes to using these semicap equipment tools…” — Mandeep Singh [16:34]

• AI Infrastructure Demands: Data Centers & Utilities

  • Demand for TSMC’s cutting-edge chips is set to stay red hot thanks to AI, as confirmed by Nvidia CEO Jensen Huang’s request for more capacity ([15:30]).
  • The next big bottleneck for hyperscalers is power, not GPUs. “Power is the biggest constraint, even more so than the GPUs, which was the case for the past three years.” — Mandeep Singh [17:48]

• What To Watch Next

  • Mandeep’s team is upping their gen AI market forecasts for 2026, with a new focus on tracking data center buildout and utility constraints ([17:05]).

3. Tyson Foods Earnings and the US Cattle Conundrum

[21:14 - 25:51]

Key Points & Insights

• Tyson’s Q4 Beat Driven By Chicken, Beef Pressures Loom

  • Tyson’s fourth quarter was strong, buoyed by chicken segment performance; operational improvements have paid off ([21:52]).
  • “For a diversified protein company, that's putting a lot of eggs in one basket, so to speak.” — Jennifer Bartashus [22:13]

• US Beef Herd Constraints: No Relief Until 2028

  • US cattle herd rebuilding is hindered by high interest rates (raising costs), drought (limiting feed), and overall capital intensity ([22:50]).
  • “It's a little bit harder in the cattle business…there have been a lot of things that have held ranchers back from increasing the size of their herds,” with no significant supply increase expected until 2028. — Jennifer Bartashus [22:51]
  • Tyson reports minor heifer retention, but not enough to reverse tightness. High beef prices are here to stay ([23:35]).

• Political Scrutiny of Meatpackers

  • President Trump has called for a DOJ investigation into the meatpacking industry, blaming foreign ownership for high prices—for Bartashus, more a political maneuver than a solution ([24:10]).
  • US imports a lot of beef for ground product (mainly from Brazil) and tariffs play a role in price dynamics ([24:36]).

• Operational Agility is Key for Tyson

  • Tyson’s future success depends on operational execution, given limited control over weather, herd rebuilding, or disease outbreaks ([25:11]).

• Thanksgiving Turkey Prices

  • Frozen turkeys are abundant and pricing should be stable; fresh birds hit by avian flu likely pricier ([25:51]).
  • “If you're more interested in the fresh bird, your price is probably going to be a little bit higher this year than it was last year.” — Jennifer Bartashus [25:51]

Notable Quotes & Memorable Moments

• On Metsera’s GLP-1 Drug:

  • “Assets look great, they're competitive, and Pfizer just stood its ground and put the bid up… what clinched it was what we'd been going on about...Nova’s deal had a risk of not being able to pass due to competition, FTC issues.” — Sam Frazelli [03:13–03:53]

• On Sector Dynamics:

  • “I don't think there's an area perhaps antibiotics set aside that is not getting a significant amount of progress across some pharma company somewhere.” — Sam Frazelli [06:11]

• On TSMC’s Dominance:

  • “TSMC, it feels like they have an unassailable moat and not just in terms of manufacturing but also their efficiency...” — Mandeep Singh [16:34]

• On AI Growth Bottlenecks:

  • “Right now the consensus is your power is the biggest constraint, even more so than the GPUs...” — Mandeep Singh [17:48]

• On US Beef Outlook:

  • “From our estimate, we're not looking at a meaningful change in supply until 2028. So, you know, expect high beef pieces, beef prices to continue.” — Jennifer Bartashus [23:31]

Key Timestamps by Segment

• Metsera Bidding War & Obesity Drug Landscape: [01:55–07:36]
• TSMC and Semiconductors’ AI Future: [10:37–18:14]
• Tyson Foods, Beef Prices, and Protein Supply Constraints: [21:14–25:51]
• Thanksgiving Turkey Insights: [25:45–25:51]

Summary Takeaways

• The end of the Metsera bidding war is a sign of shifting priorities and regulatory scrutiny in Big Pharma’s obesity race; antitrust concerns are real, but demand for innovation remains high.
• TSMC remains the irreplaceable AI chipmaker, but is stretched by capacity and supply chain realities; AI infrastructure growth is moving the market—and potentially the limits of the power grid.
• Tyson’s success is increasingly tied to its chicken segment, as supply headwinds in beef present challenges for years to come; political moves and holiday poultry prices remain top-of-mind for consumers and markets alike.